Aventis Pharmaceuticals Inc.

Paul Justin Mueller

John G Jurcak

Xu-Yang Zhao

Joseph T Strupczewski

Raymond W Kosley, Jr

Kenneth J Bordeau

Matthias Urmann

Patrick Jimonet

Stephen J Shimshock

Horst Hemmerle

Matthieu Barrague

Joseph Guiles

Rosy Sher

James Hendrix

Gregory Shutske

Thaddeus Nieduzak

Sharon Anne Jackson

Franz J Weiberth

Jennifer Beall

Harpal Gill

A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R, R, Rand X are as defined herein.

N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof

The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.

Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands

Growing community of inventors

Hoboken, NJ, United States of America

Paul Justin Mueller